No abstract

Perioperative thromboprophylaxis strategy for neurosurgical procedures is beyond to be solved and it is a timeless matter of discussion among anaesthesiologists and neurosurgeons. At the end of 2015 we developed in our hospital a consensus protocol with the neurosurgical team, similar to the latest published recommendations. (1,2) Our aim was to analyse the effect of the protocol on thrombosis prophylaxis, detection and treatment.

The conclusions presented in this work focused on the proposal for optimal biosimilar prescription criteria, the preparation of original biologics and biosimilars in the pharmacy, the management and selection of suppliers, extrapolation issues, the specific role of pharmacovigilance and risk management for the optimal use of biosimilar monoclonal antibodies.

Tranexamic acid (TXA) has been widely used after induction of anaesthesia to reduce bleeding in cardiac surgery with cardiopulmonary bypass (CPB). Whereas, TXA was reported to be associated with increased incidence of thrombotic complications. To reduce the risk of adverse outcomes associated with TXA, we began administrating TXA after CPB since July 1, 2011. This retrospective study was to observe whether the administration of TXA after CPB could reduce postoperative complications.